In December 2019 a novel coronavirus was detected in Wuhan Metropolis of Hubei Province-China. Owing to a excessive charge of transmission from human to human, the brand new virus known as SARS-CoV-2 differed from others by its unexpectedly fast unfold. The World Well being Group (WHO) described the latest coronavirus epidemic as a world pandemic in March 2020. The virus unfold triggered a well being disaster (the COVID-19 illness) inside three months, with socioeconomic implications.
p53 Mouse Monoclonal Antibody |
|||
| 38007-100ul | SAB | 100ul | EUR 302.4 |
p53 Mouse Monoclonal Antibody |
|||
| 38007-50ul | SAB | 50ul | EUR 224.4 |
CK7 Mouse Monoclonal Antibody |
|||
| 38009-100ul | SAB | 100ul | EUR 302.4 |
CK7 Mouse Monoclonal Antibody |
|||
| 38009-50ul | SAB | 50ul | EUR 224.4 |
CK8 Mouse Monoclonal Antibody |
|||
| 38010-100ul | SAB | 100ul | EUR 302.4 |
CK8 Mouse Monoclonal Antibody |
|||
| 38010-50ul | SAB | 50ul | EUR 224.4 |
NSE Mouse Monoclonal Antibody |
|||
| 38021-100ul | SAB | 100ul | EUR 302.4 |
NSE Mouse Monoclonal Antibody |
|||
| 38021-50ul | SAB | 50ul | EUR 224.4 |
HSV Mouse Monoclonal Antibody |
|||
| 38056-100ul | SAB | 100ul | EUR 302.4 |
HSV Mouse Monoclonal Antibody |
|||
| 38056-50ul | SAB | 50ul | EUR 224.4 |
p65 Mouse Monoclonal Antibody |
|||
| BF8005 | Affbiotech | 50ul | EUR 540 |
MBP Mouse monoclonal Antibody |
|||
| BF8010 | Affbiotech | 100ul | EUR 420 |
p53 Mouse monoclonal Antibody |
|||
| BF8013 | Affbiotech | 100ul | EUR 420 |
H2A Mouse monoclonal Antibody |
|||
| BF8014 | Affbiotech | 100ul | EUR 420 |
PCNA Mouse Monoclonal Antibody |
|||
| 21801-100ul | SAB | 100ul | EUR 302.4 |
PCNA Mouse Monoclonal Antibody |
|||
| 21801-50ul | SAB | 50ul | EUR 224.4 |
PCNA Mouse Monoclonal Antibody |
|||
| 37978-100ul | SAB | 100ul | EUR 302.4 |
PCNA Mouse Monoclonal Antibody |
|||
| 37978-50ul | SAB | 50ul | EUR 224.4 |
EGFR Mouse Monoclonal Antibody |
|||
| 37996-100ul | SAB | 100ul | EUR 302.4 |
EGFR Mouse Monoclonal Antibody |
|||
| 37996-50ul | SAB | 50ul | EUR 224.4 |
No authorised targeted-therapies can be found for COVID-19, but. Nonetheless, it’s foreseen that antibody-based remedies could present a direct remedy for sufferers. Present neutralizing antibody improvement research primarily goal the S protein among the many structural parts of SARS-CoV-2, which mediates the cell entry of the virus via the angiotensin changing enzyme 2 (ACE2) receptor of host cells.
This evaluate goals to supply a number of the neutralizing antibody improvement methods for SARS-CoV-2 and in vitro and in vivo neutralization assays.
Key phrases: COVID-19; SARS-CoV-2; animal fashions; show applied sciences; human monoclonal antibody; human scFv; neutralizing antibodies; neutralizing assays.
Antibody Responses after Classroom Publicity to Instructor with Coronavirus Illness, March 2020
After getting back from Europe to the USA, on March 1, 2020, a symptomatic trainer obtained constructive check outcomes for extreme acute respiratory syndrome coronavirus 2. Of the 21 college students uncovered to the trainer within the classroom, serologic outcomes recommended previous an infection for two.Classroom contact could end in virus transmission.
Key phrases: 2019 novel coronavirus illness; COVID-19; SARS-CoV-2; United States; adolescents; classroom; coronavirus illness; respiratory infections; extreme acute respiratory syndrome coronavirus 2; trainer; viruses; zoonoses.
Virus particular antibody – primarily based cures for the pressing prevention and remedy of Ebola virus illness
The Ebola virus (member of Ebolavirus genus Filoviridae household) is the etiologic agent of extraordinarily hazard human illness with excessive mortality charges (as much as 90%). A very powerful parts of spectrum of therapeutics for particular prophylactic and present of illness, attributable to Ebola virus, are prepares, primarily based on virus particular antibodies (convalescent’s plasma, geterologic immunoglobulins, monoclonal antibodies.
The usage of completely different class therapeutics, primarily based on virus particular antibodies, the potential enhancements of its composition and technique of its utility for particular prophylactic and present of illness, attributable to Ebola virus, are thought-about on this evaluate.
Immunoglobulin (IG) Antibody |
|||
| abx024071-200ug | Abbexa | 200 ug | EUR 1011.6 |
Yolk Immunoglobulin Antibody |
|||
| abx110397-500ug | Abbexa | 500 ug | EUR 360 |
Immunoglobulin M (IgM) Antibody |
|||
| abx139088-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx104924 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx104928 | Abbexa |
|
|
Immunoglobulin D (IgD) Antibody |
|||
| 20-abx172868 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx172869 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx172870 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx172871 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx172872 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx172873 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx172874 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx172875 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx172879 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx172880 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx172881 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx172882 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx176899 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx176900 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx176901 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx176902 | Abbexa |
|
|
Immunoglobulin D (IgD) Antibody |
|||
| 20-abx176907 | Abbexa |
|
|
Immunoglobulin D (IgD) Antibody |
|||
| 20-abx176908 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx176909 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx176910 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx176911 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx176912 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx176913 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx176925 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx176926 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx176927 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx176928 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx176929 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx216165 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| abx139555-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin E (IgE) Antibody |
|||
| abx139556-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin E (IgE) Antibody |
|||
| abx139557-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin M (IgM) Antibody |
|||
| abx139561-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin D (IgD) Antibody |
|||
| abx139962-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin A (IgA) Antibody |
|||
| abx140208-01mg | Abbexa | 0.1 mg | EUR 376.8 |
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx132324 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx132398 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| abx018247-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin A (IgA) Antibody |
|||
| abx018248-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin A (IgA) Antibody |
|||
| abx018249-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin M (IgM) Antibody |
|||
| abx018250-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin M (IgM) Antibody |
|||
| abx018251-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin G (IgG) Antibody |
|||
| abx018252-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin G (IgG) Antibody |
|||
| abx018253-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin G (IgG) Antibody |
|||
| abx018254-100ug | Abbexa | 100 ug | EUR 460.8 |
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx101281 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx101282 | Abbexa |
|
|
Immunoglobulin A (IgA) Antibody |
|||
| 20-abx101283 | Abbexa |
|
|
Immunoglobulin E (IgE) Antibody |
|||
| 20-abx101284 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101285 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101286 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101287 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101288 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101289 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101290 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101291 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101292 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101293 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101294 | Abbexa |
|
|
Immunoglobulin G (IgG) Antibody |
|||
| 20-abx101295 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx101296 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx101297 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx101298 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx101299 | Abbexa |
|
|
Immunoglobulin M (IgM) Antibody |
|||
| 20-abx101300 | Abbexa |
|
|
Вирус Эбола (представитель рода Ebolavirus семейства Filoviridae) является этиологическим агентом особо опасного заболевания, летальность которого достигает 90%.
- Важнейшими компонентами спектра средств экстренной профилактики и лечения заболевания, вызванного вирусом Эбола, являются препараты на основе вирусспецифических антител (плазма реконвалесцентов, гетерологичные иммуноглобулины, моноклональные антитела).
- Целью настоящего обзора является анализ эффективности медицинских средств защиты на основе вирусспецифических антител для экстренной профилактики и лечения заболевания, вызванного вирусом Эбола. В обзоре рассмотрено использование различных классов препаратов на основе вирусспецифических антител и возможное
- совершенствование их состава и стратегии применения при экстренной профилактике и лечении заболевания, вызванного вирусом Эбола.
Key phrases: Ebola virus; convalescent’s plasma of blood; geterologic immunoglobulin; hemorrhagic fever; monoclonal antibodies; particular prophylactic and present; particular antibodies.
